Robert A. Freedman

Co-Chair, Capital Markets & Public Companies

Partner, Corporate  

San Francisco 650.335.7292


Leveraging more than 25 years of experience, Rob provides a wide range of corporate and securities legal services to innovative late-stage and public companies in the life sciences and technology industries. He represents issuers and underwriters in IPOs, follow-on offerings and private placements of equity and debt securities. Rob also advises boards and management as an outside general counsel on day-to-day corporate and securities matters, including corporate governance, public company reporting, and stock exchange rules and requirements.

Rob co-chairs Fenwick’s capital markets and public companies group, helping clients raise capital, navigate risk, and tell a story through filings and disclosures over the long term. For example, he represented Loxo Oncology in its IPO, multiple follow-on offerings and its $8 billion acquisition by Eli Lilly. He has also represented Dexcom, a leader in continuous glucose monitoring, for more than 15 years, from its IPO in 2005 to numerous public and private offerings of equity and debt. Rob is committed to a company’s myriad legal needs through its full lifecycle.

Ranked as a top capital markets lawyer by Chambers USA and Chambers Global, Rob is regularly sought after for his thought leadership. He is a lead author of the firm’s Technology and Life Sciences IPO Survey and co-chairs the Practising Law Institute’s How to Prepare an Initial Public Offering 2019​ program.

Representati​ve Initial Public Offerings

  • Aeglea BioTherapeutics
  • AnaptysBio
  • Audentes Therapeutics
  • Castlight Health
  • Corium International
  • Cowen and Company
  • Dermira
  • Dexcom
  • Goldman Sachs
  • Loxo Oncology
  • Morphic Holding
  • Obalon Therapeutics 
  • Piper Jaffray & Co.
  • Passage Bio
  • ServiceNow
  • Shutterfly
  • Sierra Oncology
  • Silver Spring Networks
  • Stoke Therapeutics ​
  • Sutro Biopharma
  • Upwork

Representati​ve Mergers and Acquisitions

  • Loxo Oncology in its $8B acquisition by Eli Lilly
  • OncoGenex Pharmaceuticals in its merger with Achieve Life Science
  • Castlight Health in its acquisition of Jiff
  • Corium in its $504M acquisition by Gurnet Point Capital
  • KalVista Pharmaceuticals in its share purchase agreement with Carbylan Therapeutics
  • Dexcom in its acquisition of SweetSpot Diabetes Care
  • in its $847M acquisition by
  • Alpha Innotech in its acquisition by Cell Biosciences
  • Data Domain in its $2.4B acquisition by EMC
  • Cisco Systems in its $3.2B acquisition of WebEx Communications
  • Macromedia in its $3.4B merger with Adobe

Awards and Recognition

  • Chambers Global ranked Rob as a top capital markets lawyer (2020)
  • Best Lawyers named Rob among “The Best Lawyers in America” for his work in corporate law and securities and capital markets law (2020)
  • Chambers USA ranked Rob as a top capital markets lawyer (2019)
  • LMG Life Sciences recognized Rob as a Star (2019)
  • US News recognized Rob for his excellence in securities and capital markets law and corporate law (2019)
  • The Legal 500 recognized Rob for his capital markets practice (2019, 2018, 2017, 2016)